FMP
Addex Therapeutics Ltd
ADXN
NASDAQ
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
7.86 USD
-0.045 (-0.573%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. Timothy Mark Dyer
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex...
CIK
0001574232
ISIN
US00654J2069
CUSIP
00654J107
Address
Chemin des Mines, 9
Phone
41 22 884 1555
Country
CH
Employee
23
IPO Date
Feb 12, 2020
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
ADXN Financial Summary
CIK
0001574232
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
00654J107
ISIN
US00654J2069
Country
CH
Price
7.86
Beta
1.87
Volume Avg.
40.64k
Market Cap
11.63M
Shares
-
52-Week
5.6-27.9
DCF
-0.1
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.37
P/B
-
Website
https://www.addextherapeutics.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ADXN News
It looks like there's no news available.
